Back to Top

Informing, inspiring, and advancing global innovation to support a healthy, sustainable future

For Immediate Release

Blood Biomarkers for Detecting Brain Injury in COVID-19 Patients

Contact: Kathryn Ryan
914-740-2250
kryan@liebertpub.com

Mary Ann Liebert, Inc.
140 Huguenot Street
New Rochelle, NY 10801
(914) 740-2100 or (800) M-LIEBERT
Fax (914) 740-2101
www.liebertpub.com

New Rochelle, NY, November 17, 2020—COVID-19 can directly cause neurologic symptoms and long-term neurological disease. Elevations of blood biomarkers indicative of brain injury have been reported in the blood and cerebrospinal fluid of COVID-19 patients. Clinical application of blood biomarkers to improve medical management of COVID-19 patients is reported in the peer-reviewed Journal of NeurotraumaClick here to read the article now.

“The COVID-19 pandemic poses significant risks for acute and persistent neurological deficits, as well as possible increased risk for neurodegenerative diseases,” state Ronald Hayes, PhD, Banyan Biomarkers, and coauthors. “The use of blood biomarkers of brain injury integrated with additional existing diagnostic tools with big dataset analytics could provide timely, cost effective approaches to address this increasingly urgent unmet medical need.”

“Although presented in the context of a review article, the manuscript represents so much more,” says John Povlishock, PhD, Editor-in-Chief of Journal of Neurotrauma. “The paper concisely reviews the increased risks of the COVID-19 patient for persistent neurological deficits, psychiatric disorders, and potential neurodegenerative diseases, while describing mechanisms of the CNS penetrance and action of the virus. The paper provides not only an assessment of the challenges presented by the effects of COVID-19 on the brain, but also provides specific recommendations to address them. In all, this review masterfully argues that many of the technologies needed to probe the effects of the COVID-19 virus on the brain are in hand and can be rapidly applied.”

About the Journal
Journal of Neurotrauma is an authoritative peer-reviewed journal published 24 times per year in print and online that focuses on the latest advances in the clinical and laboratory investigation of traumatic brain and spinal cord injury. Emphasis is on the basic pathobiology of injury to the nervous system, and the papers and reviews evaluate preclinical and clinical trials targeted at improving the early management and long-term care and recovery of patients with traumatic brain injury. Journal of Neurotrauma is the official journal of the National Neurotrauma Society and the International Neurotrauma Society. Complete tables of content and a sample issue may be viewed on the Journal of Neurotrauma website.

About the Publisher
Mary Ann Liebert, Inc., publishers is known for establishing authoritative peer-reviewed journals in promising areas of science and biomedical research. A complete list of the firm’s 90 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

the firm’s 90 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

Mary Ann Liebert, Inc.
140 Huguenot Street
New Rochelle, NY 10801
(914) 740-2100 or (800) M-LIEBERT
Fax (914) 740-2101
www.liebertpub.com